Raytelligence offers products and sevices for non-contact monitoring vital signs of humans, that is respiration, heartbeat and motion patterns based on the company’s own 60 GHz radar technology.
The rights issue of maximum SEK 10.8 million is carried out to provide funds to accelerate the company’s commercialisation.
Augment is acting as financial advisor to Raytelligence in connection with the transaction.